Welcome to our dedicated page for Fortrea Holdings news (Ticker: FTRE), a resource for investors and traders seeking the latest updates and insights on Fortrea Holdings stock.
Fortrea Holdings Inc. reports news on its role as a global contract research organization serving the life sciences industry. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services for biopharmaceutical, biotechnology, medical device and diagnostic customers.
Recurring Fortrea updates include quarterly and annual financial results, book-to-bill trends, guidance, debt and capital actions, executive and board matters, equity award disclosures and technology used in clinical trial operations. Company announcements also cover platforms such as Fortrea Intelligent Technology and Xcellerate, which support trial workflow, oversight and site-facing processes.
Fortrea (Nasdaq: FTRE) reported financial results for Q1 2024 with revenues of $662.1 million, a GAAP net loss of $81.6 million, and adjusted EBITDA of $29.5 million. The company plans to divest assets related to Endpoint Clinical and Patient Access businesses. The book-to-bill ratio was 1.11x, with a backlog of $7.4 billion. Fortrea aims to be a top choice for clinical research organizations and is focused on differentiation to drive growth.
Fortrea, a leading global contract research organization (CRO), has rescheduled the release of its first quarter 2024 financial results to May 13, 2024. This delay is due to ongoing accounting and discontinued operations matters following a recent asset divestiture agreement. The company will host a conference call on the release date to discuss the financial results and conduct a Q&A session.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.